ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: TH-PO1090

Inflammatory Markers in Pediatric Nephrolithiasis

Session Information

Category: Mineral Disease

  • 1204 Mineral Disease: Nephrolithiasis

Authors

  • Kusumi, Kirsten, Akron Children''s Hospital, Akron, Ohio, United States
  • Ketz, John, Nationwide Children''s Hospital, Columbus, Ohio, United States
  • Schwaderer, Andrew L., Nationwide Children''s Hospital, Columbus, Ohio, United States
Background

Kidney stones associate with higher rates of heart attack/stroke and low bone mineral density/fractures. The mechanism of this association remains unknown; inflammation may be key. Our objective is to determine if pediatric stone formers have inflammation.

Methods

Urine was collected from 11 stone formers and 16 controls; 12-17 years old with radiographic evidence of stones. Exclusion criteria: metabolic acidosis, CKD II or >, immobilization, hyperlipidemia, hypertension, diabetes, inflammatory bowel disease, rheumatoid arthritis, or lupus. Urine was tested via a Mesoscale V-Plex Human Cytokine panel inflammation array. Levels were normalized to creatinine to control for concentration. Statistics by paired T-Test; p value <0.05 was significant.

Results

Five inflammatory markers were significantly increased in stone children: Il-13, Il-1B, MIP-1B, Il-12/Il-23p40 and Il-16.

Conclusion

This is the first evidence of inflammation in pediatric stone formers; this population is free of confounding diseases that are common in adults. Identification of inflammation in pediatric stone formers may be the first step in delineating the molecular mechanisms linking stone, bone and cardiovascular disease.

Table 1
Inflammatory MarkerControl (pg/mg)Stone former (pg/mg)P value
IL-12/IL-23P400.1670.4030.017
IFNY000.407
Il-10000.999
Il-12p70000.056
Il-1300.080.003
Il-1B0.0110.2940.01
Il-2000.937
Il-4000.067
Il-60.2550.3660.394
Il-817.450.150.162
TNFA000.157
Eotaxin5.1588.2730.107
Eotaxin-31.0450.8860.514
IP-107.8888.9320.544
MCP-49.59314.220.568
MCP-195.37119.70.301
MCD1.5191.9570.438
MIP-1A000.371
MIP-1B2.5825.8290.0004
GM-CSF0.0470.1140.441
TARC00.0040.396
Il-150.2410.1340.394
Il-1600.28630.013
Il-17000.183
Il-1A1.5874.5490.365
IL-70.490.5060.862
TNFB000.688
VEGFA152.5171.50.08
IL-5none detectednone detectedNA

MW: Mann–Whitney test